Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome

Boparai, K.S.; Reitsma, J.B.; Lemmens, V.; van Os, T.A.M.; Mathus-Vliegen, E.M.H.; Koornstra, J.J.; Nagengast, F.M.; van Hest, L.P.; Keller, J.J.; Dekker, E.

Published in:
Gut

DOI:
10.1136/gut.2009.200741

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome

K S Boparai, J B Reitsma, V Lemmens, T A M van Os, E M H Mathus-Vliegen, J J Koornstra, F M Nagengast, L P van Hest, J J Keller, E Dekker

ABSTRACT

Introduction Hyperplastic polyposis syndrome (HPS) is characterised by the presence of multiple colorectal hyperplastic polyps and is associated with an increased colorectal cancer (CRC) risk. For first-degree relatives of HPS patients (FDRs) this has not been adequately quantified. Reliable evidence concerning the magnitude of a possible excess risk is necessary to determine whether preventive measures, like screening colonoscopies, in FDRs are justified.

Aims and methods We analysed the incidence rate of CRC in FDRs and compared this with the general population through person-year analysis after adjustment for demographic characteristics. Population-based incidence data from the Eindhoven Cancer Registry during the period 1970–2006 were used to compare observed numbers of CRC cases in FDRs with expected numbers based on the incidence in the general population.

Results A total of 347 FDRs (41% male) from 57 pedigrees were included, contributing 11 053 person-years of follow-up. During the study period, a total of 27 CRC cases occurred among FDRs compared to five expected CRC cases (p<0.001). The RR of CRC in FDRs compared to the general population was 5.4 (95% CI 3.7 to 7.8). Four FDRs satisfied the criteria for HPS. Based on the estimated HPS prevalence of 1:3000 in the general population the projected RR of HPS in FDRs was 39 (95% CI 13 to 121).

Conclusions FDRs of HPS patients have an increased risk for both CRC and HPS compared to the general population. Hence, as long as no genetic substrate has been identified, screening colonoscopies for FDRs seem justified but this needs to be prospectively evaluated.

INTRODUCTION

Hyperplastic polyposis syndrome (HPS) is a condition characterised by the presence of multiple hyperplastic polyps (HPS) spread throughout the colon and is associated with an increased colorectal cancer risk.1–5 Because of this increased risk of malignant progression, HPS patients undergo endoscopic surveillance with removal of polyps or surgical colonic resection. Although an increased risk of colorectal cancer (CRC) for these patients has been established, it is uncertain whether an increased risk of CRC and/or HPS for first-degree relatives (FDRs) exists and consequently whether preventive measures, like screening colonoscopies, should be performed in this group.

Although HPS was initially considered to be non-familial, previously published case series report that up to 50% of HPS patients have a FDR with CRC.2,6 In addition, the presence of HPS has been described in multiple family members2,3,7–9. Based on these reports, a yet unidentified underlying genetic defect seems to play a role in at least some HPS cases.

Concordantly, previous studies have shown that HPS is caused in a small proportion of patients by a germline mutation in the MUTYH gene resulting in a germline mutation in the MUTYH gene resulting

Significance of this study

What is already known about this subject?

▸ Patients with hyperplastic polyposis syndrome (HPS) have an increased risk of developing colorectal cancer (CRC)
▸ First-degree relatives (FDRs) of patients with HPS are also believed to have an increased risk of CRC
▸ It is, however, unknown what proportion of all FDRs is at risk of developing CRC
▸ Reliable evidence concerning the magnitude of this possible excess risk is necessary to adequately inform FDRs regarding their risk of CRC

What are the new findings?

▸ In this study, the CRC incidence rate in FDRs was compared with the general population through person-year analysis with adjustment for demographics
▸ During the study period, a total of 27 CRC cases occurred among 347 FDRs compared to five expected CRC cases (p<0.001) resulting in a RR of 5.4 (95% CI 3.7 to 7.8)
▸ Four FDRs satisfied the criteria for HPS. Based on the estimated HPS prevalence in the general population the projected RR of HPS in FDRs was 39 (95% CI 13 to 121)

How might it impact on clinical practice in the foreseeable future?

▸ Based on these finding we conclude that FDRs have an increased risk for both CRC and HPS compared to the general population
▸ As long as no genetic substrate has been identified screening colonoscopies for FDRs seem justified

Departments of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands; Department of Clinical Epidemiology & Biostatistics, Academic Medical Center, Amsterdam, The Netherlands; Department of Research, Comprehensive Cancer Centre South, Eindhoven, The Netherlands; Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands; Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands.

Correspondence to Dr E Dekker, Department of Gastroenterology and Hepatology, Academic Medical Center Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands; e.dekker@amc.uva.nl

Revised 25 January 2010
Accepted 3 February 2010
Published Online First 28 June 2010

doi:10.1136/gut.2009.200741

1222 1225
in a phenotype of multiple conventional adenomas and serrated polyps.\textsuperscript{2,10} However, in the overall majority it is unclear what proportion of FDRs are at risk of developing CRC and/or HPS. Furthermore, the possible mode of inheritance is unknown. Families have been reported previously from which both an autosomal recessive and autosomal dominant inheritance could be considered.\textsuperscript{2,6,9}

Thus, to adequately inform FDRs regarding their risk of CRC and/or HPS, reliable evidence concerning the magnitude of this excess risk is necessary. The aim of this study was to estimate the incidence rate of CRC and HPS in FDRs of HPS patients and to compare this with the general population so as to determine whether preventive measures such as screening colonoscopies in this group are justified.

METHODS

Besides HPs, HPS patients often have multiple sessile serrated adenomas (SSAs), traditional serrated adenomas and conventional adenomas. HPs and SSAs have been shown to be histologically very similar and difficult to differentiate microscopically with only moderate concordance.\textsuperscript{11-14} For this reason HPS was defined as at least five histologically diagnosed HPs and/or SSAs proximal to the sigmoid colon, of which two are greater than 10 mm in diameter, or more than 20 HPs and/or SSAs distributed throughout the colon.\textsuperscript{15} This is a variation of the original HPS criteria defined by the WHO which only involves HPs (\textit{\geq}30).\textsuperscript{1} HPS patients (proband) from four medical centres in The Netherlands were included when satisfying the above mentioned diagnostic criteria for HPS. Of these patients, family history data were obtained through face-to-face and telephone interviews or by examining data from the Departments of Clinical Genetics. Patients with a known germline \textit{MUTYH} mutation or bi-allelic \textit{MUTYH} mutation were known excluded from the study.

Risk assessment for CRC was performed by including person-years at risk for CRC from 1 January 1970 until 1 January 2009 (censory date). FDRs were considered at risk from birth until date of CRC diagnosis, date of death or the censoring date. It was presumed that from the time the proband developed CRC FDRs would have a higher chance of receiving endoscopic screening for CRC which could cause a bias when comparing with the general population. For this reason, person-years at risk also ended at the date of CRC diagnosis in the proband if applicable.

Person-years at risk were stratified according to 5-year age group, gender and calendar year using SAS software, version 9.1. Similarly stratified population-based data from the Eindhoven Cancer Registry were used to compare the incidence of CRC in FDRs with that of the general population.\textsuperscript{15} The expected CRC incidence in FDRs was calculated by applying the age-, gender- and calendar-specific incidence rates of the general population to the composition and follow-up years of the FDR cohort. The observed versus expected number of CRC cases were formally compared by calculating a RR and 95% CI. This RR is calculated by taking the ratio of observed to expected number of cases and its CI by assuming a Poisson distribution of cases. Two-sided \textit{p} values <0.05 were considered statistically significant.

RESULTS

First-degree relatives

In this study a total of 347 FDRs (142 male) from 57 pedigrees were included, contributing 11 053 person-years of follow-up (figure 1). The median age at end of follow-up was 60 years (IQR: 44–71). These FDRs consisted of 165 (48%) siblings, 100 (55%) parents and 82 (17%) children. In total, 27 FDRs, consisting of 14 parents, 12 siblings and one child were excluded because (1) they died before 1 January 1970 (n=17) or (2) information regarding that individual was unknown (n=10).

Colorectal cancer

During the study period, a total of 27 (8%) CRC cases occurred among FDRs. The median age of CRC occurrence was 62 years (IQR: 57–78) and 15 (56%) were of the male gender (table 1). The RR of CRC in FDRs compared to the general population was 5.4 (95% CI 3.7 to 7.8). One additional CRC case occurred outside the study period (before 1970) and was therefore not included. There were no excluded CRC cases in FDRs which developed after CRC diagnosis in the proband. Of the 27 FDRs with CRC, four probands developed CRC at a later stage. In total, 16/57 (28%) probands were diagnosed with CRC during the study period.

The difference in CRC risk between men and women within the FDR group was not statistically different (RR: 1.9, 95% CI 0.9 to 4.1, Pearson \textit{\chi}^2 test: \textit{p}=0.089). Also when comparing this between siblings (brothers and sisters) and non-siblings (parents and children) within the FDR group, no significant difference was seen (RR: 1.0, 95% CI 0.4 to 2.5, Pearson \textit{\chi}^2 test: \textit{p}=0.96). Other malignancies recorded in the study period included breast cancer (n=10), gastric cancer (n=2), ovarian cancer (n=2) and others (n=12).

Polyps

Conventional white-light colonoscopies were performed in 65/347 (19%) of FDRs. Reasons for endoscopy were not recorded. In this group, 35/65 (54%) individuals had colorectal lesions from whom 24 the histology was known. In seven FDRs multiple histologically confirmed HPs (\textit{\geq}5) were identified at a median age of 58 years (range: 50–75) of which six had HPs proximal to the rectosigmoid colon (supplemental table). Four of these FDRs from four different pedigrees satisfied the criteria for HPS.
In probands (ie, patients with HPS) a higher CRC incidence was observed (16/57: 28%) during the study period compared to FDRs (27/347: 8%). This finding was expected considering that not all FDRs also had HPS. However, of the four FDRs with HPS, two (50%) had CRC suggesting that the presence of multiple serrated polyps is associated with CRC. These findings are concordant with a previous large HPS cohort study which showed that the number of serrated polyps was positively correlated with the risk of CRC.

In a previous flexible sigmoidoscopy screening study performed in a large cohort of asymptomatic individuals (n=40673), the true prevalence of HPS was estimated to be 1:3000 after subsequent colonoscopies.\textsuperscript{17} Colorectal polyps, particularly HPS, do not necessarily cause symptoms and thus could be left undiagnosed in individuals if an endoscopy is not performed. In this study only 19% of FDRs received an endoscopy. Consequently, although our study concluded that FDRs have an increased risk of having HPS, an under-estimation of the true prevalence of HPS in FDRs seems likely. In addition, of the FDRs with colorectal polyps the histology was unknown in 11/58 cases. Of these individuals five were reported to have multiple polyps of unknown histology. It seems possible that these individuals could potentially have HPS too but this could not be verified.

Alternatively, because the prevalence of HPS in the general population was based on a previous screening sigmoidoscopy study, a degree of uncertainty exists regarding this estimation. This uncertainty decreases the validity of our projected RR of HPS in FDRs.

With regard to the mode of inheritance, our study did not show a significant difference in CRC incidence between siblings and non-siblings (RR: 1.0, 95% CI 0.4 to 2.5, Pearson $\chi^2$ test: $p=0.96$). These findings make it difficult to postulate a preference for either a vertical or a horizontal transmission. Also concerning polyp incidence in FDRs, although 3/4 (75%) of FDRs with HPS were siblings, these numbers are too few to make any conclusions about the mode of inheritance. These results are in concordance with previously reported FDRs with HPS (supplemental table: six siblings vs seven non-siblings). Alternatively, the presence of FDRs with an intermediate phenotype of <10 HPS, suggest that a co-dominant mode of inheritance, involvement of several low penetrance genes, high risk genes with reduced penetrance or even environmental factors may play a role.

Regarding the management of FDRs, this study suggests that as long as no underlying genetic cause has been identified, screening colonoscopies are justified for this group. In addition, this study showed that of the 27 FDRs with CRC, only four probands had CRC, implying that screening colonoscopies should be performed in all FDRs, independent of CRC presence in the proband. However, future large prospective screening studies in FDRs are required to further evaluate the incidence of CRC and HPS and the optimal screening programme in this group. Until these future data are acquired, we advise a provisional screening programme from the age of 35 years or 5 years younger than the lowest incidence age of HPS reported in the family. Subsequent surveillance colonoscopies could then be performed at 6 year intervals with shorter intervals when polyps are detected.

Competing interests None.

Ethics approval This study was conducted in accordance with the research code of our institutional medical ethical committee on human experimentation, as well as in agreement with the Helsinki Declaration of 1975, as revised in 1983.

Provenance and peer review Not commissioned; externally peer reviewed.
Diarrhoea and weight loss in an immunosuppressed patient

CLINICAL PRESENTATION

A 74-year-old Caucasian female presented with a 12 month history of non-bloody, culture-negative diarrhoea associated with weight loss of 10 kg. She denied any extragastrointestinal manifestations. She had previously undergone orthotopic liver transplantation for primary biliary cirrhosis 12 years ago. Her immunosuppression was mycophenolate mofetil 500 mg twice daily for the past 2 years. She had previously been on ciclosporin immunosuppression was mycophenolate mofetil 500 mg twice daily for the past 2 years. She had previously been on ciclosporin.

QUESTIONS

What is the diagnosis?

What is the best management?

See page 1302 for the answers

Safa Al-shamma,1 Mark Fox,1 Fiona Campbell,2 Paul Collins,1 Martin Lombard1

1Department of Gastroenterology, Royal Liverpool University Hospital, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK; 2Department of Pathology, Royal Liverpool University Hospital, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK

Editor’s quiz: GI snapshot

Figure 1 Ascending colon.

Correspondence to Dr Martin Lombard, Department of Gastroenterology, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK; martin.lombard@rlbuht.nhs.uk

Competing interests None.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Gut 2010;59:1225. doi:10.1136/gut.2009.198986
Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome


_Gut_ 2010 59: 1222-1225 originally published online June 28, 2010
doi: 10.1136/gut.2009.200741

Updated information and services can be found at:
http://gut.bmj.com/content/59/9/1222.full.html

These include:

References
This article cites 23 articles, 8 of which can be accessed free at:
http://gut.bmj.com/content/59/9/1222.full.html#ref-list-1

Article cited in:
http://gut.bmj.com/content/59/9/1222.full.html#related-urls

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Endoscopy (1372 articles)
Colon cancer (2889 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/